Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

Enanta Pharmaceuticals Inc. diskutieren

Enanta Pharmaceuticals Inc.

WKN: A1T7BJ / Symbol: ENTA / Name: Enanta / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

12,70 €
4,96 %

Einschätzung Buy
Rendite (%) -23,49 %
Kursziel 43,82
Veränderung
Endet am 08.08.24

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock.
Ratings data for ENTA provided by MarketBeat

Einschätzung Sell
Rendite (%) -13,61 %
Kursziel 12,75
Veränderung
Endet am 09.08.24

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was downgraded by analysts at JPMorgan Chase & Co. from a "neutral" rating to an "underweight" rating. They now have a $14.00 price target on the stock.
Ratings data for ENTA provided by MarketBeat

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ENTA provided by MarketBeat

Einschätzung Buy
Rendite (%) 7,63 %
Kursziel 44,85
Veränderung
Endet am 19.09.24

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $48.00 price target on the stock.
Ratings data for ENTA provided by MarketBeat

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ENTA provided by MarketBeat

Einschätzung Buy
Rendite (%) 53,01 %
Kursziel 28,27
Veränderung
Endet am 23.10.24

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $48.00 to $30.00. They now have a "buy" rating on the stock.
Ratings data for ENTA provided by MarketBeat

Einschätzung Buy
Rendite (%) 41,11 %
Kursziel 21,01
Veränderung
Endet am 21.11.24

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at JMP Securities from $42.00 to $23.00. They now have an "outperform" rating on the stock.
Ratings data for ENTA provided by MarketBeat

Einschätzung Buy
Rendite (%) 41,11 %
Kursziel 25,58
Veränderung
Endet am 21.11.24

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its price target lowered by analysts at HC Wainwright from $30.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for ENTA provided by MarketBeat

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for ENTA provided by MarketBeat